 Katherine Tzou
Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2019 | 1046 | 0.920 |
Why?
| | Radiosurgery | 3 | 2019 | 389 | 0.610 |
Why?
| | Prostate-Specific Antigen | 4 | 2022 | 166 | 0.590 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2017 | 1067 | 0.450 |
Why?
| | Databases, Factual | 2 | 2019 | 1441 | 0.440 |
Why?
| | Radium | 2 | 2022 | 4 | 0.320 |
Why?
| | Salvage Therapy | 6 | 2017 | 154 | 0.320 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2022 | 52 | 0.300 |
Why?
| | Bone Neoplasms | 2 | 2022 | 247 | 0.260 |
Why?
| | Radiation Injuries | 2 | 2013 | 147 | 0.190 |
Why?
| | Melanoma | 2 | 2022 | 792 | 0.180 |
Why?
| | Prostatectomy | 4 | 2017 | 102 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 166 | 0.170 |
Why?
| | Aged, 80 and over | 8 | 2019 | 7899 | 0.150 |
Why?
| | Neuroma, Acoustic | 1 | 2019 | 55 | 0.140 |
Why?
| | Testicular Neoplasms | 1 | 2019 | 114 | 0.140 |
Why?
| | Prognosis | 4 | 2019 | 4060 | 0.140 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.130 |
Why?
| | GATA2 Transcription Factor | 1 | 2017 | 14 | 0.130 |
Why?
| | Kallikreins | 1 | 2016 | 27 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2017 | 97 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2022 | 832 | 0.120 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 8 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 691 | 0.110 |
Why?
| | Data Collection | 1 | 2018 | 651 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1243 | 0.110 |
Why?
| | Prostate | 1 | 2016 | 172 | 0.110 |
Why?
| | Glioblastoma | 1 | 2017 | 334 | 0.110 |
Why?
| | Patient Reported Outcome Measures | 1 | 2018 | 437 | 0.100 |
Why?
| | Rectal Diseases | 1 | 2013 | 24 | 0.100 |
Why?
| | Radiotherapy, Conformal | 1 | 2013 | 73 | 0.100 |
Why?
| | Aged | 9 | 2019 | 24666 | 0.100 |
Why?
| | Male | 15 | 2022 | 69893 | 0.100 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1240 | 0.100 |
Why?
| | Middle Aged | 10 | 2019 | 34487 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5194 | 0.090 |
Why?
| | Brachytherapy | 1 | 2013 | 131 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 380 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1536 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2022 | 16315 | 0.090 |
Why?
| | Neoplasm Metastasis | 3 | 2019 | 674 | 0.090 |
Why?
| | Embolization, Therapeutic | 1 | 2013 | 242 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1328 | 0.080 |
Why?
| | Treatment Failure | 1 | 2011 | 353 | 0.080 |
Why?
| | Humans | 17 | 2022 | 140898 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2016 | 853 | 0.070 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1396 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2013 | 740 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1786 | 0.060 |
Why?
| | Adult | 6 | 2019 | 39134 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2007 | 217 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2017 | 280 | 0.060 |
Why?
| | Medulloblastoma | 1 | 2007 | 218 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2004 | 100 | 0.050 |
Why?
| | Neoplasms, Experimental | 1 | 2004 | 174 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1320 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2004 | 451 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2022 | 11125 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2004 | 359 | 0.040 |
Why?
| | Watchful Waiting | 1 | 2019 | 85 | 0.040 |
Why?
| | Lomustine | 1 | 2017 | 14 | 0.030 |
Why?
| | Risk Factors | 3 | 2017 | 10430 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1275 | 0.030 |
Why?
| | Neurosurgical Procedures | 1 | 2019 | 197 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 78 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2017 | 207 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2017 | 307 | 0.030 |
Why?
| | Aminoquinolines | 1 | 2016 | 18 | 0.030 |
Why?
| | Ipilimumab | 1 | 2016 | 40 | 0.030 |
Why?
| | Administration, Topical | 1 | 2016 | 149 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2004 | 2003 | 0.030 |
Why?
| | Coloring Agents | 1 | 2016 | 96 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1496 | 0.030 |
Why?
| | Risk Assessment | 2 | 2015 | 3484 | 0.030 |
Why?
| | Contrast Media | 1 | 2017 | 470 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 907 | 0.030 |
Why?
| | Organs at Risk | 1 | 2013 | 35 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1261 | 0.030 |
Why?
| | Organ Sparing Treatments | 1 | 2013 | 36 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2013 | 143 | 0.030 |
Why?
| | Yttrium Radioisotopes | 1 | 2013 | 63 | 0.030 |
Why?
| | Radiation Protection | 1 | 2013 | 39 | 0.030 |
Why?
| | Microspheres | 1 | 2013 | 142 | 0.020 |
Why?
| | Radiography | 1 | 2013 | 844 | 0.020 |
Why?
| | United States | 2 | 2019 | 15195 | 0.020 |
Why?
| | Young Adult | 2 | 2019 | 13646 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7749 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1962 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1968 | 0.020 |
Why?
| | Female | 5 | 2019 | 75540 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6944 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2760 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2782 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2156 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3336 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3724 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 236 | 0.010 |
Why?
| | Immunologic Memory | 1 | 2004 | 359 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1031 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1271 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2004 | 1141 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22027 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 6257 | 0.010 |
Why?
| | Infant | 1 | 2007 | 9790 | 0.010 |
Why?
| | Child, Preschool | 1 | 2007 | 11462 | 0.010 |
Why?
| | Mice | 1 | 2004 | 18057 | 0.000 |
Why?
| | Animals | 1 | 2004 | 37579 | 0.000 |
Why?
|
|
Tzou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|